Search | Clinical Trials Finder

Conditions: Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: JNJ-74699157; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more

Conditions: Advanced Solid Tumor, NSCLC, CRC
Interventions: JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor); Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more

Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Interventions: avutometinib (VS-6766) and adagrasib; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: Sotorasib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 20 more

Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 90
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 74 more

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions: MRTX849, TNO155; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 17
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 9 more

Conditions: Lung Neoplasm Malignant
Interventions: MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab, Rescue Medications; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Clermont, Florida • Chicago, Illinois • Portland, Oregon

Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions: Darlifarnib, Cabozantinib, Adagrasib; Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Non-Small Cell Lung Cancer
Interventions: JDQ443, docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Renton, Washington

Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
Interventions: JDQ443, trametinib, Ribociclib, cetuximab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 9
States / cities: Birmingham, Alabama • Stamford, Connecticut • Miami Beach, Florida + 6 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Carfilzomib, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Sotorasib; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Non-small Cell Lung Cancer
Interventions: VIC-1911, sotorasib; Drug
Lead sponsor: Vitrac Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more

Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Interventions: GDC-6036, Atezolizumab, Cetuximab, Bevacizumab, Erlotinib, GDC-1971, Inavolisib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Orange, California + 5 more

Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions: JDQ443, TNO155, tislelizumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more

Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Lung Cancer, Lung Cancer (NSCLC), Locally Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
Interventions: Olomorasib, Pembrolizumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions: Divarasib, Sotorasib, Adagrasib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more

Conditions: Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions: IMM-6-415; Drug
Lead sponsor: Immuneering Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more

Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions: avutometinib and sotorasib, avutometinib and sotorasib and defactinib; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more

Conditions: Non Small Cell Lung Cancer, NSCLC, KRAS G12C
Interventions: Adagrasib, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Ryan Gentzler, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Columbus, Ohio • Charlottesville, Virginia • Richmond, Virginia

Conditions: Non Small Cell Lung Cancer
Interventions: AMG 510, MVASI; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions: JDQ443; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Interventions: Sotorasib, Ladarixin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Garden City, New York • Mineola, New York • New Hyde Park, New York + 1 more

Search by objective public record fields.

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Ladarixin With Sotorasib in Advanced NSCLC - Phase II